Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis.
作者信息
Gorai Surajit, Rathore Gyanesh, Das Kinnor
机构信息
Department of Dermatology, Day Care Building, Apollo Multispeciality Hospital, Kolkata, West Bengal, India.
出版信息
Indian Dermatol Online J. 2024 Jun 26;15(4):701-705. doi: 10.4103/idoj.idoj_569_23. eCollection 2024 Jul-Aug.
Abstract
摘要
相似文献
1
Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis.司美替尼——美国食品药品监督管理局批准的用于治疗神经纤维瘤病的新药综合综述
Indian Dermatol Online J. 2024 Jun 26;15(4):701-705. doi: 10.4103/idoj.idoj_569_23. eCollection 2024 Jul-Aug.
2
A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.司美替尼治疗1型神经纤维瘤病相关丛状神经纤维瘤的综述
Ann Pharmacother. 2022 Jun;56(6):716-726. doi: 10.1177/10600280211046298. Epub 2021 Sep 18.
3
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.西罗莫司治疗 1 型神经纤维瘤病和丛状神经纤维瘤患儿：SPRINT 的通俗语言摘要。
Future Oncol. 2024 May;20(14):877-890. doi: 10.2217/fon-2023-0565. Epub 2024 Feb 22.
4
Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.1 型神经纤维瘤病中的精准肿瘤学：使用单细胞 RNA 测序定量分析丛状神经纤维瘤对司美替尼的差异敏感性。
J Neurooncol. 2024 Aug;169(1):147-153. doi: 10.1007/s11060-024-04711-5. Epub 2024 May 13.
5
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.西罗莫司在儿童 1 型神经纤维瘤病和无症状不可手术丛状神经纤维瘤患者中的应用，这些患者存在发生与肿瘤相关发病率的风险。
Neuro Oncol. 2022 Nov 2;24(11):1978-1988. doi: 10.1093/neuonc/noac109.
6
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.人群药代动力学和神经纤维瘤病 1 型伴不可切除丛状神经纤维瘤儿科患者中司美替尼及其 N-去甲基代谢物的暴露-反应。
Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26.
7
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.司美替尼在1型神经纤维瘤病相关丛状神经纤维瘤中的活性
N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.
8
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.FDA 批准概要：Selumetinib 用于丛状神经纤维瘤。
Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. doi: 10.1158/1078-0432.CCR-20-5032. Epub 2021 Mar 12.
9
Selumetinib: First Approval.色瑞替尼：首次批准。
Drugs. 2020 Jun;80(9):931-937. doi: 10.1007/s40265-020-01331-x.
10
Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas.食物对1型神经纤维瘤病相关丛状神经纤维瘤青少年患者中司美替尼药代动力学及胃肠道耐受性的影响。
Neurooncol Adv. 2024 Mar 16;6(1):vdae036. doi: 10.1093/noajnl/vdae036. eCollection 2024 Jan-Dec.
本文引用的文献
1
Neurofibromatosis Type 1 with a Giant Diffuse Plexiform Neurofibroma Invading the Liver.神经纤维瘤病 1 型伴巨大弥漫性丛状神经纤维瘤侵犯肝脏。
Intern Med. 2023 Oct 15;62(20):2971-2975. doi: 10.2169/internalmedicine.1372-22. Epub 2023 Feb 15.
2
Selumetinib for Refractory Pulmonary and Gastrointestinal Bleeding in Noonan Syndrome.索拉非尼治疗努南综合征伴发难治性肺和胃肠道出血
Pediatrics. 2022 Oct 1;150(4). doi: 10.1542/peds.2022-056336.
3
Effect of food on capsule and granule formulations of selumetinib.食物对 selumetinib 胶囊和颗粒制剂的影响。
Clin Transl Sci. 2022 Apr;15(4):878-888. doi: 10.1111/cts.13209. Epub 2022 Feb 15.
4
Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.针对 ERK 丝裂原活化蛋白激酶级联反应治疗 KRAS 突变型胰腺癌。
Adv Cancer Res. 2022;153:101-130. doi: 10.1016/bs.acr.2021.07.008. Epub 2021 Sep 2.
5
Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.司美替尼治疗1型神经纤维瘤病儿科患者的疗效与安全性：一项系统评价和Meta分析
Neurology. 2022 Mar 1;98(9):e938-e946. doi: 10.1212/WNL.0000000000013296. Epub 2022 Jan 11.
6
Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.使用MEK抑制剂治疗丛状神经纤维瘤：新治疗方案的初步结果
Neuropediatrics. 2022 Feb;53(1):52-60. doi: 10.1055/s-0041-1740549. Epub 2021 Dec 14.
7
A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.司美替尼治疗1型神经纤维瘤病相关丛状神经纤维瘤的综述
Ann Pharmacother. 2022 Jun;56(6):716-726. doi: 10.1177/10600280211046298. Epub 2021 Sep 18.
8
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.人群药代动力学和神经纤维瘤病 1 型伴不可切除丛状神经纤维瘤儿科患者中司美替尼及其 N-去甲基代谢物的暴露-反应。
Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26.
9
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.精准医学时代的神经纤维瘤病：MEK 抑制剂的发展和 Selumetinib 的最新成功
Curr Oncol Rep. 2021 Mar 15;23(4):45. doi: 10.1007/s11912-021-01032-y.
10
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.FDA 批准概要：Selumetinib 用于丛状神经纤维瘤。
Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. doi: 10.1158/1078-0432.CCR-20-5032. Epub 2021 Mar 12.
Zotero 插件